According to a new study, the REGN CoV-2 medicine, which Norway has purchased, contributes to 70% fewer hospitalizations and deaths in corona patients in the risk group.
The antibody treatment REGN CoV-2, which is produced by the company Regeneron, became famous when it was used in the treatment of former US President Donald Trump.
In retrospect, several studies have shown promising results, and the authorities in several countries, including Norway, have purchased the medicine.
In a comprehensive phase 3 study, the drug was given to patients in the risk group infected with COVID-19 who were not hospitalized.
Compared with a group treated with placebo medicine, patients receiving REGN CoV-2 had 70% fewer deaths and hospitalizations, according to a press release from the pharmaceutical company Roche Norway.
A total of 4,567 patients participated in the study. Compared with placebo, it was also found that patients treated with REGN-CoV-2 had fewer days with symptoms (a median of ten days versus 14 days).
“The number of patients with COVID-19 continues to increase both in Norway and globally, and the need for both vaccines and effective treatment is great. We hope this antibody treatment can be a tool for doctors who are in a very demanding situation and high-risk patients who become infected,” medical director Karsten Bruins Slot in Roche Norway stated.
At the end of February, it became known that Norway had purchased a limited number of doses of RAIN CoV-2. The Norwegian Directorate of Health did not want to comment on the price or the number of doses that had been ordered.
Germany has previously bought the medicine for EUR 2,000 – or just over NOK 20,000 – per dose.
Source: © NTB Scanpix / #Norway Today / #NorwayTodayNews
Do you have a news tip for Norway Today? We want to hear it. Get in touch at email@example.com